 |
Suzhou, China and Mölndal, SwedenMay 28, 2026 /PRNewswire/ — Suzhou Ribolia Biopharmaceutical Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals (collectively “Ribolia”) announced that they have submitted a Phase II Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for RBD1119, a small interfering RNA (siRNA) drug candidate for the treatment of coronary artery disease. Recently, leveraging the RiboGalSTARTM liver-targeted siRNA platform, Ribolia has simultaneously advanced the clinical development of multiple siRNA drugs in areas including atrial fibrillation and venous thromboembolism, building a globally leading anticoagulant/antithrombotic siRNA landscape. This initiative aims to systematically address the fundamental treatment gaps in thromboembolic diseases. This CTA submission for coronary artery disease marks another significant milestone in Ribolia’s strategic expansion in the antithrombotic field and underscores its confidence in continuously broadening the application of siRNA in this area.
Coronary artery disease (CAD) is a leading cause of morbidity and mortality among cardiovascular disease patients worldwide. Its core triggers include atherosclerotic plaque formation and resulting thrombotic complications such as myocardial infarction and ischemic events. Current antiplatelet and anticoagulant therapies are standard clinical practices, yet the risk of thrombotic events in patients with stable coronary artery disease (CAD) after optimized standard treatment remains inadequately controlled. A major limitation of existing therapies is the high risk of bleeding, which constrains treatment intensity and long-term medication regimens for many patients. Therefore, to address the current challenges in antithrombotic therapy, there is an urgent need to develop novel treatments that can achieve efficient and long-lasting prevention and treatment of thromboembolism while controlling bleeding risk, delivering therapeutic outcomes that balance efficacy and safety.
Dr. Anders Gabrielsen, Chief Medical Officer of Ribolia, stated: “Cardiovascular disease is one of the key therapeutic areas for Ribolia. We are very pleased to advance another antithrombotic siRNA drug to the next stage of clinical development. This once again demonstrates our firm commitment to providing clinical solutions with a better benefit-risk profile for patients who currently lack adequate treatment, using leading siRNA therapies.”
About Ribolia
Suzhou Ribolia Biopharmaceutical Co., Ltd. (Ribolia, 06938.HK) is a global biopharmaceutical company focused on the development and commercialization of small interfering RNA (siRNA) drugs. Driven by its proprietary and innovative siRNA technology platform, the company has built a rich and differentiated product pipeline targeting major disease areas such as cardiovascular metabolism, liver, and kidney diseases. Ribolia is dedicated to providing revolutionary treatment options for patients worldwide through continuous innovation.
For more information, please visit: www.ribolia.com.